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Studying the action of mechanisms of type I interferon (IFN) provides the insight to elu-
cidate the cause and therapy for autoimmune diseases. There are high IFN responses in
some diseases such as connective tissue diseases, but low responses in multiple sclero-
sis. Distinct IFN features lead us to understand pathology of a spectrum of autoimmune
diseases and help us to search genetic changes, gene expression, and biomarkers for
diagnosis, disease progression, and treatment response.
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PROLOGUE
EVOLUTION OF TYPE I INTERFERONS: IMPLICATIONS FOR
AUTOIMMUNITY AND CELL PROTECTION
Interferons (IFNs) were present in early bony fish during the
Devonian Period, 400,000,000 years ago. Fish have branched into
more species than all other vertebrates combined, and changes
in their proteins evolved in parallel with taxonomic diversity.
Sequence and structural similarities in fish IFNs suggest that there
was an earlier ancestor in common with mammals. Present-day
fish IFN has introns and in that way resembles human IFN-lambda,
a type III IFN. Mammalian type I IFN has no introns, and may
have arisen from retrotransposition of spliced RNA to intron-
less DNA with the same sequence as the parent gene (1). DNA
without introns is more easily duplicated, leading to many sub-
types. Transcription from DNA without introns is rapid and can
bypass mechanisms that can be derailed by virus infections. Anti-
viral IFN genes would therefore have a selection advantage during
fevers.
Interferons vary widely between species of present-day fish.
Salmon have 11 subtypes of type I and III IFN; zebrafish have two
group 1 and two group 2 subtypes. Subtypes of IFN likely evolved
to effectively target different viruses in vertebrates. Viruses bind
toll-like receptors (TLRs) 3, 7, 8, and 9 and retinoic acid-inducible
gene-I (RIG-I) receptors. These fish receptors then induce IFNs
which activate or induce type I IFN receptors (IFNARs), and
in turn, signaling proteins (JAK1, TYK2), transcription factors
(STAT1), and many IFN-stimulated gene (ISG) proteins (such as
IRF, MxA, PKR, and viperin) (2). All are present in humans.
The human type I IFN family comprises 13 IFN-α, 1 IFN-β, 1
IFN-κ (keratinocytes), 1 IFN-ω (Table 1). IFN-τ is a related vari-
ant found only in the ruminant trophectoderm, important early in
pregnancy. IFN-δ is produced by pig trophoblasts. IFN-ζ/limitin
is present in mice.
Humans have three type III IFN-λs (aka IL-29, IL-28A, and
IL-28B) which bind a different receptor (IL-10Rβ and IL-28Rα
chains), often on epithelial cells and liver cells. IFN-lambda has
introns. Only restricted cell types express the unique type III
IFNAR, and thus it may have fewer side effects. It is produced
by plasmacytoid dendritic cells (pDCs) and induces IL-6, IL-8,
and IL-10, and activates type II monocytes. It is anti-proliferative,
but only for several tumor cell subtypes.
Viruses were likely to have been early targets of IFNs in evo-
lutionary history. There is intense selective pressure to rapidly
destroy viruses and virus-infected cells. Human interferons induce
proinflammatory cytokines and chemokines such as CXCL10
(IP10), and turn on hundreds of anti-viral genes such as MxA,
viperin, 2′,5′-OAS, and PKR. IFNs also activate cytolytic T cells,
NK cells, Th1 cells, macrophages, and cells from other tissues, and
induce apoptosis of infected cells. (Control of inflammation is
discussed below.)
Interferons regulate a 1000 genes (3, 4). Many of these genes
are not anti-viral. Some IFN-regulated genes shape the innate and
adaptive immune systems, some modify transcription, some are
anti-proliferative and pro-apoptotic to combat cancer, other genes
control fertility, fatty acid oxidation, free radical neutralization,
energy metabolism, and cell protection and tissue repair. These
functions are a leap beyond the anti-viral role of IFNs. Virus-
independent benefits suggest that IFN responses evolved to “clean
up the mess” after a virus infection (Ed Croze, personal communi-
cation, 2007). Subnormal IFN levels, as in multiple sclerosis (MS),
could disturb immune regulation and also diminish cell protec-
tion. Therapy of MS with type I IFNs reverses these disturbances.
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Table 1 | Interferons in mice vs. humans.
Mouse Man
Type I IFNs 14 IFN-α genes 13 IFN-α genes (12 proteins)
19 kDa, 165–166 aa Four have alleles that differ between strains
10 Glycosylated 2 Glycosylated
IFN-α4 promoter binds IRF3 IFN-α4 promoter binds IRF3
20 kDa, 22 kDa glycosylated, 166 aa 1 IFN-β 1 IFN-β
IFN-β promoter binds IRF3 IFN-β promoter binds IRF3
22 kDa and glycosylated, 187 aa 1 IFN-ε 1 IFN-ε
25 kDa, 180 aa 1 IFN-κ 1 IFN-κ
20 kDa, 172 aa 1 IFN-ω None
19 kDa, 182 aa 1 IFN-ζ (limitin) 1 IFN-ζ (limitin)
Type II IFN 1 IFN-γ 1 IFN-γ
17 kDa
Type III IFN
21 kDa, 26–35 glycosylated None IFN-l1 (IL-29)
22 kDa, 24 glycosylated IFN-l2 (IL-28A) IFN-l2 (IL-28A)
21 kDa, 24 glycosylated IFN-l3 (IL-28B) IFN-l3 (IL-28B)
Signaling P-STAT proteins P-STAT proteins
STAT1a 91 kDa P-Y701-STAT1 P-Y701-STAT1
P-S727-STAT1 P-S727-STAT1
STAT1b 84 kDa P-Y701-STAT1 P-Y701-STAT1
STAT2 113 kDa P-Y689-STAT2 P-Y690-STAT2
No Y833 – truncated (76)* P-Y833-STAT2
No Y841 – truncated P-Y841-STAT2
No STAT2 induction of P-STAT4 (76) P-STAT2 induces P-STAT4
STAT4 86 kDa Type I IFNs induce Th1 P-STAT4 induces IFN-g, Th1
Type I IFNs induce Th1, but reports in MS are mixed
EAE vs. MS EAE MS
The target Antigen-induced No known antigen (ADEM is Ag-induced)
Therapy Improvement with pure IFN-β Most improve with IFN-β therapy (∼85% have a low
IFN signature) (∼15% have higher IFN signature; less
response to IFN-β therapy)
*“Humans do not provide a good model for mouse immunology” from Ref. (76).
IFN SIGNALING, KINETICS, AND SPECIES DIFFERENCES
The primary source of IFN is from pDCs (IFN-α> IFN-β produc-
tion), fibroblasts – the major producers of IFN-β (IFN-β> IFN-α),
macrophages, and endothelial cells. pDC are only 1% of DC.
Myeloid dendritic cells (mDCs) secrete IL-12 and other cytokines,
but only small amounts of IFN.
Interferons signal through a rapid cascade. Type I IFN is
secreted within an hour of stimulation with virus or poly(IC),
a synthetic analog of viral double-stranded RNA (dsRNA). Viral
nucleic acids are recognized by pattern receptors (described below)
that activate IRF3, which then turns on IFN-β and IFN-α1 syn-
thesis. These first subtypes of IFN bind IFNARs and activate
IRF7 in surrounding cells to induce multiple other type I IFN
subtypes/species.
The cell surface type I IFNAR has two-chains, IFNAR1 and
IFNAR2 which activate TYK2 and JAK1. Phospho-JAK1 and
TYK2 then phosphorylate STAT1 (P-Tyr701-STAT1) and STAT2
(P-Tyr-STAT2) proteins which complex with IRF9 (p48) (ICSBP)
to form IFN-stimulated gene factor 3 (ISGF3). Like type I IFNs,
IFN-lambda induces ISGF3. Within 10 min after IFN activates
its receptor, the ISGF3 binds the IFN-stimulated response ele-
ment (ISRE) of a large group of gene promoters. DNA-bound
P-Y-STAT1 is sometimes then phosphorylated on serine 727
within ∼10 min (forming P-S-STAT1) (5) which boosts the sig-
nal for a subset of IFN-regulated genes. STAT2 has no serine
phosphorylation site.
TYPE I IFN REGULATION AND LOCALIZATION OF IFN
PRODUCTION
Once the receptors above are activated, a sequence of intra-
cellular signals amplifies IFN secretion. IRF3 is phosphory-
lated, binds to DNA promoters, and then IFN-β and IFN-α1
(IFN-α4 in mice) are rapidly secreted. These two IFNs then
bind the type I IFNAR on the same and other cells and acti-
vate IRF7 which binds to promoters for other IFN-α sub-
types.
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Other intracellular signal transduction molecules modify the
JAK-STAT pathway, including, PI3K, CRKL, RAP1, PKC-δ and ε,
and p38 in the MAPK cascade (6). These converging proteins are
cell-specific. These pathways enhance effects of type I IFNs, but
perhaps the most important interaction is with IFN-γ.
Type II IFN-γ is the prototypic immunoregulatory Th1
cytokine, but it is only distantly related to type I IFNs and has only
weak anti-viral effects. It activates STAT1 on tyrosine. P-Y-STAT1
homodimers bind to the gamma-activated site (GAS), present in
a set of promoters that are different from the type I IFN ISRE that
is activated by the STAT1/STAT2/IRF9 complex. IFN-γ-activated
P-Y-STAT1 can interact with IFN-β-induced P-Y-STAT1. Preincu-
bation with IFN-γ “primes” cells for a more vigorous response to
IFN-β.
Interferon signaling differs between mice and men. In humans,
activation of STAT2 then phosphorylates STAT4, which can turn
on more cytokine genes. In some mouse strains, however, STAT2
is truncated, and does not activate STAT4 (Table 1). Thus, the
murine experimental allergic encephalomyelitis (EAE) model of
MS suffers from being an antigen-specific model of a disease with
no known antigen, and because inflammation in EAE is regulated
by interferon signaling that is missing part of the human signaling
cascade.
Some downstream genes are rapidly induced (e.g., anti-viral
and immunoregulatory genes); others take longer to plateau (e.g.,
genes with secondary induction, e.g., dual oxidase 2) (4). Kinet-
ics also vary between cells. For instance, IL-10 mRNA production
by activated monocytes is maximal at 4–8 h and is inhibited by
IFN-β. In activated T cells, the peak is at 24 h and IL-10 mRNA is
amplified by IFN-β (7).
Interferon-β, compared to the individual subtypes of IFN-α,
induces a larger number of genes in human fibrosarcoma cells, and
does so more quickly (3). IFN-β binds to the IFNAR for a longer
time than IFN-α (8), explaining the differential gene induction.
Perhaps because of the greater number, but more balanced port-
folio, of induced genes, IFN-βhas fewer side effects than equivalent
anti-viral doses of IFN-α. IFN-β is also more effective than IFN-α
in some therapies. Despite the traditional use of IFN-α subtype to
treat some forms of cancer, IFN-β is actually more potent against
several types of cancer at equivalent anti-viral titers of both IFNs
(9). It is also more effective in MS therapy. (Cytoprotective effects
are discussed with MS, below.)
Does IFN-β cross the blood-brain barrier (BBB)? Although CSF
IFN levels are only 1/1000 of serum levels in a normal monkey
(10), the damaged BBB in MS and EAE could allow IFN to cross.
In humans, circumstantial evidence suggests that IFN-β has direct
effect on the CNS. IL-10 levels in CSF rise after IFN-β-1a therapy
(11) and black hole formation is reduced by IFN-β-1b (12). In
mice with EAE, IFN-induced mRNA is clearly present in the CNS,
after controlling for the effects of EAE and IFN-induced mRNA
outside the CNS (13). Thus, IFN-βmay have direct effects on brain
cells in MS.
TRIGGERS FOR TYPE I IFN PRODUCTION
Virus components that induce type I IFNs include exogenous
virus RNA or DNA and associated proteins, vaccines which are
attenuated viruses or contain virus components, and endogenous
retroviruses that make up ∼8% of human DNA. Exuberant
responses to viruses or to abnormally processed DNA from
dying cells and their nucleic acids can activate the immune sys-
tem and lead to autoimmune diseases such as systemic lupus
erythematosus (SLE).
Receptor families recognize conserved pathogen-associated
molecular patterns (PAMPs; i.e., “danger” from viral nucleic acids
and other motifs) and viruses. These receptors include TLR,
RIG-I, melanoma differentiation-associated protein 5 (MDA5),
CD11b/CD18 (Mac1), STING (DNase II), as well as the Trex
system. Each virus can be detected by multiple PAMP receptors.
Toll-like receptors were originally characterized in fruit flies,
where they recognize a developmental growth factor and con-
trol antimicrobial responses in adult flies. In humans, 10 types of
TLR recognize bacterial components, RNA, and DNA. Fibroblasts
express TLR3 on their surface. Other, intracellular, sensors detect
viruses after they are internalized or generated inside cells. They
also sense abnormally processed nucleic acids in connective tissue
diseases after Fc receptors internalize DNA-Ab complexes. TLR3
is endosomal in monocytes and mDCs (TLR3 is not in pDC).
Virus RNA is recognized after phagocytosis and internalization,
or after enveloped viruses penetrate the cell by endocytosis. After
binding dsRNA or pIC, human TLR3 is activated within acidi-
fied cytoplasmic endosomes (14). TLR3 activates TRIF, and then
kinases (IKKε, TBK1) that phosphorylate IRF3 and IRF7 (below).
TLR7 and TLR8 bind single-stranded RNA (ssRNA), poly-IC,
and imiquimod. TLR9 binds intracytoplasmic viral or bacterial
CpG-rich DNA. TLR7, 8, and 9 are present in pDC.
The RNA helicases, RIG-I and MDA5, bind short and long
viral dsRNA, or pIC. Homologs of all of these receptors, with the
exception of the OAS system, are present in fish where they sense
pathogens and induce IFNs and many ISG.
IRF3 is constitutively expressed at high levels in most cells. IRF7
is present at only low levels,mainly in immune cells especially pDC,
but is necessary for the initial induction of IFNs. Activated IRF3
induces IFN-β and IFN-α1 (IFN-α4 in mice) which prime the type
I IFN system for a much stronger response. After virus exposure,
rapidly secreted IFN-β binds the IFNAR and induces and activates
intracellular IRF7 (at 4 h), while IRF3 is degraded. IRF7 broadens
the response by inducing multiple IFN-α genes in pDC which and
activate pDC, T cytolytic, Th1, and NK cells. In parallel, virus-
exposed conventional DC and monocytes secrete cytokines such
as IL-12 plus low amounts of IFN-α1 and IFN-β.
TLR7, 8, and 9 are expressed at high levels in pDC, and activate
MyD88. These TLRs activate IRF7 which induces transcription
of some IFN-β plus high levels of multiple types of IFN-α in
pDC (15). Ligation of RIG-I and MDA5 activate transcription
factors IRF3 and NF-κB, which travel to the nucleus and initiate
transcription of type I IFNs.
CONSEQUENCES OF EXCESS STIMULATION BY DNA, RNA,
BACTERIA, AND CYTOKINES
Influenza infections elevate type I IFNs in serum and pulmonary
secretions. In Sjögren’s syndrome, foci of inflammation in salivary
glands are positive for IFN-α, and serum IFN levels are elevated.
In SLE and Sjögren’s disease, high interferon levels and lack of
immune regulation cause damage to target organs. Surprisingly,
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because it is an immunologically privileged site, the brain also
exhibits IFN expression or binding. An early paper showed IFN-
α-positive macrophages, IFN-γ-positive astrocytes and microglia,
and occasional IFN-β-positive astrocytes and macrophages, within
active chronic MS brain lesions (16). During chronic hepatitis C
therapy, IFN-α (5 MU TIW) reduces PET activity by 10% in the
pre-frontal cortex (17), and 3 MU TIW causes gradual slowing of
VEP over 1 year (18). Hepatitis C in these patients may have had
additive effects with IFN-α. In contrast, VEP slowing is likely not
seen with IFN-β therapy, as P300 potentials are stable or improved
(19). Excessive CNS IFN levels cause encephalopathy in Aicardi–
Goutières syndrome, Cree encephalitis, and cerebral malaria, v.i.
(20), and possibly in SLE and Sjögren’s disease.
The Trex system is an intracellular monitor for products of
endogenous retroviruses. Trex1 (DNAse III) is the major 3′,5′-
exonuclease in humans. The single-exon gene codes for a cytosolic
protein that is induced by the IRF3-dependent IFN-stimulated
response to foreign DNA (21). It edits DNA by stripping off
one stand of ssDNA and metabolizes intranuclear DNA; resid-
ual ssDNA that escapes from the nucleus can trigger an immune
response. Remnants of ancient retroviruses human endogenous
retrovirus (hERV) that have incorporated into the DNA comprise
∼8% of the human genome, and retroelements may outnumber
our genes by 100-fold (21). These hERV are not complete virions,
but portions can be transcribed, and do generate ssDNA fragments
and proteins. hERV DNA is degraded by Trex1. In Trex1 knock-
out mice, 22% of the DNA in inflamed myocardium is coded by
endogenous retroviruses, vs. 7% in wild type mice (21), indicating
that Trex1 is needed to destroy these retroviral genes. Reverse-
transcribed DNA that induces IFN production is the principle
cause of autoimmunity in these mice. Defects in Trex1 lead to
high circulating levels of foreign DNA, which triggers type I IFN
production and autoantibody production.
Trex1 deficiency causes constitutive activation of the systems
that control ATM-dependent double-strand breaks and cell cycle
checkpoints. Induction of ATM for DNA-damage monitoring also
activates p53 and BRCA1, leading to fewer tumors, self-renewal of
hematopoietic stem cells, thymocyte survival, but less apoptosis
of autoreactive immune cells. This could amplify autoimmune
disease.
A defective Trex1 gene is common in Canadian Cree Indi-
ans, and causes excessive interferon production. This leads to
Cree Indian Encephalopathy, or Aicardi–Goutières syndrome,
an encephalopathy associated with lupus-like symptoms (22).
Excessive CSF IFN-α (42 IU/ml) in affected children (Pierre
Lebon, Paris) mimicked congenital viral infection, but associated
chilblains (pernio) pointed to SLE and autoimmunity, and IFN-α.
These children have: (1) progressive microcephaly and failure to
attain neurodevelopmental milestones, beginning in early infancy;
(2) recurrent viral, bacterial, and fungal infections; (3) cerebral
atrophy, white matter attenuation, and calcifications of basal gan-
glia, white matter, and/or cerebellum on CT scan; (4) perivascular
chronic inflammatory infiltrates in cerebral hemisphere white
matter and hyperplasia of vascular endothelial linings; and (5)
polyclonal hypergammaglobulinemia. They sometimes have cor-
roborative features such as: (1) dystonic posture; (2) systemic
autoimmune abnormalities – high ALT and Abs to cardiolipin,
ssDNA, dsDNA, and RNA-protein complexes; (3) splenomegaly
and lymphadenopathy; (4) CSF pleocytosis with high CSF IFN-α
and Ig; high blood CD8 “suppressor” and B cells; (5) intermit-
tent hyperpyrexia; (6) chronic active Epstein–Barr virus (EBV) or
CMV infection or persistent viral excretion; (7) similarly affected
siblings; and (8) acrocyanosis with autoamputation (23, 24). With
this “chilblain lupus” from Trex1 deficiency, cold exposure causes
cyanosis of toes and fingers because of damage to capillaries.
Eighty percent of families with Aicardi–Goutières syndrome have
mutations in one of four nuclease genes – the exonuclease Trex1
[chromosome 3p21 (AGS1)] or the genes for all three components
of the ribonuclease H2 enzyme complex (AGS2, 3, and 4).
In SLE, apoptotic products of PMN, T cells, and macrophages
are not cleared correctly by macrophages. Apoptotic blebs con-
tain modified chromatin, and neutrophil extracellular traps are
released by dying neutrophils (NETosis). Abnormally processed
nucleic acid-containing debris circulates as phospho-DNA that
is recognized as a virus, or Ab-DNA neoantigens, that activate
FcR and TLR of DC and the BCR of B cells. Chromatin, double-
stranded DNA, and RNA-binding ribonucleoproteins activate an
autoimmune circuit and production of IFN-α/β by pDCs and
anti-dsDNA Abs by autoreactive B cells.
Excess local IFN-α damages the CNS. Encephalopathy develops
when IFN-α is overexpressed in astrocytes (25). Transgenic mice
develop early mineralization around blood vessels in the thala-
mus at 2 months, calcium crystals in cerebellum at 12 months, and
perivascular CD4+ T cell infiltrates in the CNS. Some pediatric
infections lead to high CSF IFN-α (“TORCH,” from Toxoplasmo-
sis, Other, Rubella, CMV, HSV), with sequelae of CNS calcifica-
tions and brain atrophy. Chronic exposure to IFN-α in cultured
astrocytes increases GFAP expression, reduces proliferation, and
causes hypertrophy and activation (25, 26), reflecting the changes
from high CNS IFN-α in Aicardi–Goutières syndrome.
In MS, HERV DNA and antibodies to HERV proteins appear in
serum, CSF, and brain (27). Activated immune cells release HERV
nucleic acids into the cytosol. This could induce type I IFNs in
immune cells or the CNS in some MS patients.
“Interferon inducers” also generate non-IFN cytokines and
proteins. For instance, pIC is a potent stimulus for lympho-
cyte production of ACTH and other proteins processed from the
pro-opiomelanocortin (POMC) precursor molecule (28). IFN-α2
triples serum ACTH and cortisol 5 h after injections in patients
with hepatitis B; flu-like symptoms do not correlate with induc-
tion (29). In contrast, IFN-β-1b therapy of MS does not elevate
cortisol (30).
Environmental agents and drugs can modify IFN effects. Vit-
amin A activates STAT1 and synergizes with IFN-β (31). Oral
vitamin D3 regulates 63 genes, 62 of these were also regulated by
IFN-β-1b therapy in early MS (Munger, uncorrected data analy-
sis of BENEFIT study; personal communication, CSMC, 2013).
Statins, which lower cholesterol and are anti-inflammatory, sur-
prisingly block IFN signaling. They reduce formation of P-Y-
STAT1 and IFN-β-induced MxA production in vitro and in vivo
(32), and allow attacks of MS when added to ongoing IFN-β-1a
therapy (33) (below).
The response to exogenous or endogenous triggers has to be
tightly controlled, or unchecked immune responses will destroy
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the host (34). Excessive responses to influenza, as in the 1918
pandemic, lead to death from severe pneumonitis. Weak immune
responses, as in never-exposed youths or in octogenarians, do not
control the virus. Prior immune education usually allows rapid
clearance, manageable immune reaction, and tolerance/regulation
that allows the inflammation to subside. Tolerance should be
under stronger selective pressure than the actual anti-pathogen
response (34, 35). As a virus is cleared, the immune system tem-
pers inflammation with regulatory T cells, inhibitory receptors
for immunoglobulin Fc on immune effector cells, apoptosis and
autophagy of target cells, anti-inflammatory cytokines, and induc-
tion of intracellular suppressors of cytokine signaling (SOCS)
proteins. IFNs regulate each of these immune functions, and
regulation of each, had to evolve over eons.
Prevention of anti-self responses in an individual are honed
over a lifetime by environmental events which generate a complex
immune repertoire to combat danger. If the environmental guid-
ance is missing, holes in the repertoire can trigger autoimmunity
to self antigens. If certain antigens or levels of interferon are in
excess, immune responses could be excessive and can cross react
with self, triggering autoimmunity.
DISEASE WITH HIGH SERUM TYPE I IFN LEVELS AND HIGH
RESPONSES TO IFN: SLE, CNS SJÖGREN’S SYNDROME,
NMO, AND A MINORITY OF MS PATIENTS
Early reports identified a unique “acid labile” type I IFN in serum
of patients with SLE and HIV infection (36). Type I IFN is resis-
tant to pH 2, but IFN-γ is destroyed on exposure to acid. Acid
sensitivity may be from have aberrant glycosylation of some sub-
types of IFN-α in connective tissue disease and HIV. More recent
studies of patients with SLE demonstrate significant increases in
serum type I IFN activity (37, 38) and excessive signatures for
IFN-induced RNA in white blood cells [in Ref. (37)]. Responses
to self DNA or viruses are inappropriately regulated in hered-
itable complex traits linked to single nucleotide polymorphisms
(SNPs) in IFN-regulatory genes (TYK2, IRF5, STAT4, TNFAIP3,
and TREX1) and diverse mutations in Trex1 in 0.5–3%. In sup-
port, lupus-prone mice that are transgenic for TLR7.1 and have
excessive levels of TLR7 have more autoantibodies and early severe
lupus. High IFN-α levels correlate with SLE disease activity and
severity in some studies (24). Clinically relevant, therapy with type
I IFN causes de novo SLE or worsening of preexisting disease.
Nearly all parts of the body can be affected in SLE from the anti-
nuclear antibodies and symptoms derived from high serum IFN
levels. A constellation of damage affects skin, mucocutaneous tis-
sue, joints, kidneys, lungs, heart, and blood vessels – with immune-
complex vasculitis and thrombotic occlusions. CNS lesions are
rare, but occasionally lupus myelopathy develops with devastat-
ing vasculitis, inflammation, swelling, and demyelination over
many cord segments. In addition, serum type I IFN levels are
elevated. SLE problems that are possibly related to high serum
IFN levels include lymphopenia, myalgia and muscle weakness,
joint pain with modest infusions, significant constitutional symp-
toms – headache, body ache, malaise, and fatigue that can herald
neuropsychiatric problems (poor memory, mood swings, seizures,
and psychosis – without strokes or vasculitis, although there is
underlying small vessel vasculopathy in SLE brains). Cognitive
problems are often unrelated to SLE exacerbations, suggesting a
second mechanism of damage. Perhaps high levels of type I IFN,
and abnormally processed nucleic acids induce autoantibodies
that are specific to certain regions of the brain and interfere with
neuronal function (39) (Table 2). With disruption of the BBB
by stress or epinephrine, neurons in the amygdala are damaged
by Abs (anti-NR2) to orphan NMDA receptors. With BBB dis-
ruption from infections, auto-Abs damage hippocampal neurons
and disrupt spatial memory. In both cases the damage is excito-
toxic, without inflammation, due to Ab-mediated stimulation of
the NMDA receptor.
Interferon levels are high in serum and salivary glands in Sjö-
gren’s disease, a connective tissue disorder with dry eyes and mouth
(sicca) from inflammation of the lacrimal and salivary glands,
along with synovitis, vasculitis, and neuropathy. Classic primary
Sjögren’s syndrome typically appears in middle-aged women. CNS
involvement is usually not part of primary Sjögren’s, but a CNS
variant was recently described (Javed, below). Secondary Sjö-
gren’s syndrome coexists with SLE, polyarteritis nodosa, rheuma-
toid arthritis, scleroderma, polymyositis, and neuromyelitis optica
(NMO) (below). Glands are infiltrated by foci of memory CD4 T
cells (secreting IL-10 and IFN-γ),macrophages, and mast cells near
activated epithelial cells (IL-1β, IL-6, TNF-α). A small number of
infiltrating activated B cells produce high levels of immunoglob-
ulin, some directed against rheumatoid factor, SSA/Ro, SSB/La,
anti-nuclear antigens, aquaporin 5, and the M3 muscarinic recep-
tor. The surprising overlap between CNS Sjögren’s syndrome and
NMO (often considered an “MS variant”) is discussed below.
MULTIPLE SCLEROSIS: EPIDEMIOLOGY, IMMUNOLOGY, AND
ROLE OF IFN
Multiple sclerosis is an inflammatory CNS disease with no clear
etiology, pleomorphic clinical and MRI appearance, and huge vari-
ation in clinical course, with a transition from bi-yearly relapses
and remissions to a progressive form after∼8–15 years (40). Clin-
ical attacks plus the 10× more frequent subclinical events seen
on MRI cause cumulative damage. Attacks last 2–6 weeks, affect
any part of the CNS, and often resolve to near-baseline func-
tion. MRI lesions enhance with Gd, from leakage through the
BBB and perhaps pinocytosis by activated endothelial cells of
post-capillary venules. Lesions enhance for a month, then the
residual high-water T2 signal fades slowly or becomes a permanent
black hole reflecting damage to axons, neurons, and oligoden-
droglia. Therapy with IFN-β and some other drugs prevent Gd+
lesions but also prevent black hole formation after Gd+ lesions
appear. This suggests that MS therapies may have neuroprotective
effects.
Multiple sclerosis is more likely to arise when a first degree rel-
ative has MS (10- to 20-fold increase), and in smokers, the obese
(2×), in those with little exposure to sunlight or with low vitamin
D levels (2×), and when first EBV infection is delayed to ado-
lescence. Once MS develops, exacerbations are more frequent in
smokers (1.6×), and after infections by many different viruses or
after vaccination with certain attenuated live viruses such as yellow
fever (41). IFN-β therapy does not prevent virus infections, but it
does diminish the residual clinical deficit after a virus-induced
exacerbation of MS (42).
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Table 2 | Characteristics of demyelinating disease.
MS (40) SLE CNS Sjögren’s (58) NMO (77, 78)
MRI brain lesions Periventricular, Dawson’s fingers Gray and white matter
lesions
Centrum seniovale Hypothalamic and
periventricular in <10%
“Random” WM+GM, but predilection
for certain areas
Small to large lesions Small WM, rare large
vasculitic, and CVA lesions
Small lesions Medium to large
lesions, later in course
MRI cord lesions <1 Segment Rare extensive myelopathy >3 Segments, also
smaller lesions (58)
>3 Segments;
longitudinally extensive
Often subpial or acentric Central cord Central cord
Relapse rate q 2 year ∼Once per 5 year, on
therapy
Similar to NMO Frequent (∼2×/year)
early in the course for
NMO+patients
Progression PPMS at onset in 10% Stepwise and gradual
multi-organ failure
Progressive sicca
symptoms
None
RRMS becomes SPMS @ 8–15 year ∼Once per 5 year, on
therapy
Pathology CNS Demyelination> axonal loss “Vasculopathy”> cognitive
changes
Demyelination< axonal
damage
Demyelination< axonal
damage
Many lesions will repair Rare arteriopathy Vasculopathy Vasculopathy
Destruction by CD8 T cells and
monocytes
Cells include PMN and Eos Severe Severe and destructive
No repair
Serum marker No marker Anti-dsDNA SSA/SSB 40% Anti-AQP-4 60–75%
Anti-AQP-4 50%
Target Ag Unknown Abnormally processed
DNA and RNA
Nucleic acids, AQP-5 AQP-4
Minor salivary gland
inflammation in 100%
Serum type I IFN Low IFN-α/β High IFN-α/β High IFN-α/β High IFN-α/β
IFN-β Response by MNC Low High High High
CSF High IgG ∼Normal ∼Normal ∼Normal
OGCB 90% 10% ∼10% 20%
Triggers for exacerbation Virus, vaccination for yellow fever Virus Virus, possibly Virus; UTI (AQP-Z) (79)
Type I IFNs Possibly type I IFNs Possibly type I IFNs
Low vitamin D Sunlight
Smoking: MS onset and exacerbations Smoking: SLE onset and
exacerbations
Possibly smoking Possibly smoking
Therapy IFN-β, glatiramer, natalizumab,
fingolimod, fumarate, teriflunomide,
alemtuzumab, rituximab, laquinimod
Hydroxychloro-quine,
steroids, chemotherapy
Rituximab, steroids,
chemotherapy
Rituximab, steroids,
chemotherapy
Sunlight; vitamin D potentiates IFN-β-1b
GI parasites
Gout is rare
Pregnancy Benefit, perhaps from estriol Worse Unknown Unknown
Linked diseases ?Thyroid Connective tissue
diseases
Connective tissue
diseases
Connective tissue
diseases
?Ulcerative colitis Aicardi–Goutieres
AQP, aquaporin; GI, gastrointestinal; GM, gray matter; NMO, neuromyelitis optica; UTI, urinary tract infection;WM, white matter.
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Multiple sclerosis usually begins in the reproductive years and
is thee times more common in women than men. A subset of
patients, perhaps 25%, has a high IFN signature as well as more
clinical and MRI attacks before therapy, and these patients often do
not respond to IFN-β therapy (43, 44). They have excessive acti-
vation of monocytes and mDCs and a high type I IFN-induced
gene signature that predicts 70% of non-responders compared
to patients with normal IFN signatures. Non/poor-response was
defined as one or more attacks of 2 years on therapy (43) or three
or more new or worse MRI lesions (44). However, since high dis-
ease and MRI activity predicts more future activity, these patients
should be considered partial-responders, in the absence of an
untreated control group.
Immune studies and SNPs on GWAS implicate many genes
involved in immunoregulation or IFN signaling. HLA-DR2 has
the strongest GWAS odds ratio at 2.0; others are only 1.1–1.4, but
do include IFN-regulated genes such as Tyk2, 2′,5′-oligoadenylate
synthase (OAS1), IRF5, MxA, and many IFN-affected immune
response genes (40, 45). This suggests that environmental influ-
ences and the education of the immune system are critical in the
development of MS and its course. A Th1 bias is characteristic of
MS. As a consequence, cancers, virus infections, and allergies is less
frequent than expected in MS patients (40). A shift to Th2 immu-
nity, seen with glatiramer therapy or after parasite infestation,
reduces exacerbations of MS. IFN-β, however, does not simply
cause a shift to Th2 immunity – type I IFNs typically enhance Th1
immunity (46). In the CSF of IFN-β treated patients, however, IL-
10 is elevated (11), perhaps from IFN-β stimulation of activated T
cells (7).
It would seem that MS and connective tissue disease could have
a common etiology because they are “autoimmune.” However, MS
only rarely coincides with SLE (47), NMO is a separate entity, and
the majority of MS patients benefit from IFN-β therapy instead of
worsening (48). Importantly, the vigorous signature in SLE, Sjö-
gren’s, and NMO, contrasts with the subnormal serum type I IFN
activity and WBC responses to IFN in most MS patients (Table 2).
MULTIPLE SCLEROSIS: LOW SERUM TYPE I IFN ACTIVITY
ANDWEAK RESPONSES TO IFN
The first patients that were placed on commercially available IFN-β
showed induction of IFN-g (Th1), IL-10 (Th2) (46), and the IFN-
stimulated proteins IRF-1, IRF-2, and 2′,5′-oligoadenylate syn-
thetase (2′,5′-OAS) in mononuclear cells (MNCs) (49) (Figure 1).
However, before any therapy, IFN regulation is abnormal in MS.
Levels of these ISG products were actually low, and after IFN-β
injections, levels rose only to levels seen in unstimulated con-
trol MNC. It was apparent that IFN responses were subnormal
in MS, and that IFN-β therapy corrected IFN-induced protein lev-
els back to the normal range. Extensive experiments using flow
cytometry of IFNAR expression, Western blots of P-Y-STAT1, gel
shift assays (EMSA), transfection of MNC with an IFN-responsive
human ISRE reporter gene, and SHP levels to measure poten-
tial dephosphorylation of P-tyrosine, all showed that P-Y-STAT1
levels and P-STAT1 binding to DNA were normal and or above
normal [Reder et al., 2000, unpublished and (32)] (Figure 2).
Despite normal levels of P-Y-STAT1, however, induction of the
above-mentioned ISG and MxA, an IFN-induced anti-influenza
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FIGURE 1 | Basal IFN-regulated mRNA levels in therapy-naïve stable
RRMS (black bars) are lower than in healthy controls (white). IFN-β
therapy induces mRNA production in MS MNC (Pre-Rx vs. IFN Rx), but
levels are still at or below levels in unstimulated normal MNC (white). MNC
assayed before and 3 months after in vivo IFN-β-1b (8 MU sq qod). Early
genes are IFN-regulatory factor-1 (IRF-1; enhances signaling) and IRF-2
(negative regulator), and later gene is 2′,5′-oligo-adenylate synthetase
(2′,5′-OAS, an IFN-α/β-induced anti-viral enzyme). (Pre vs. Rx: IRF-1 and
IRF-2, p<0.02; 2′,5′-OAS, p<0.03; paired t -test). (Avg±SEM for
IFN-stimulated gene/HPRT; RT-PCR) N = 5 RRMS patients for IRFs, and 10
for 2′,5′-OAS, vs. 9 normal (46).
protein, was subnormal. It was later discovered there was a second
STAT1 phosphorylation site at serine 727 (50). In unstimulated
MNC from therapy-naive patients, P-S-STAT1 levels were low in
MS (32). P-S-STAT1 was also poorly induced by IFN-β in cultured
MNC, and this low P-S-STAT1 correlated with low levels of ISG.
This indicated that there is a fundamental defect in IFN regula-
tion that underlies MS, and that is likely to have consequences for
immune regulation, therapy, and CNS repair.
P-S-STAT1 levels are low in MNC during exacerbations and
progression (32). In vitro, induction of therapy-naïve MNC with
IFN-β induces phosphorylation of STAT1 on serine in healthy
controls and in patients with stable RRMS. In contrast, P-S-STAT1
is not induced during exacerbations and progression. A subset of
downstream genes are not induced during the IFN-resistant state
seen in active MS. MxA and viperin induction is diminished, but
other ISG such as PKR have normal expression (32, 38).
The subdued IFN response that underlies clinical disease activ-
ity in therapy-naïve MS patients has consequences for immune
regulation, and may also predict future disease activity. The IFN-
resistant state appears to be corrected by IFN-β therapy. IFN-β
injections increase IRF-1, IRF-2, 2′,5′-OAS, MxA, and viperin to
near normal levels (Figures 1 and 2) (32, 46). Type I IFNs, them-
selves, are important IFN-stimulated proteins. IFN-β injections
cause a rise in serum IFN-β that peaks at 30 min and then declines.
This elevation is soon followed by a second, prolonged rise in
serum type I IFN activity, presumably from newly induced IFN-
α plus more IFN-β (38). Finally, IFN-β therapy of MS restores
defective CD8 regulatory cell function (51), increases expression
of the inhibitory ILT3 protein on monocytes (52), and reduces
expression of costimulatory molecules on B cells (53).
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P-Ser-STAT1 kinetics in MS
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FIGURE 2 | (A) P-S-STAT1 is markedly reduced in MNC from therapy-naïve,
clinically active MS at baseline (left of dashed line), and after stimulation with
160 U/ml IFN-β (right of dashed line). (B) Area under curve of IFN-β-induced
P-S-STAT1 is high in stable RRMS and healthy controls (NL) at 60′ vs. active
MS (8 NL, 7 RRMS-s, 7 RR+SPMS-a) (p<0.001 active/progressive MS vs.
NL; ANOVA with repeated measures) (32).
Interferon-β-treated patients with ostensibly stable MS, yet
weak responses to their IFN injections, are more likely to
have attacks in the future (54). These weak responses paral-
lel the effect of neutralizing antibodies (NAbs) to IFN-β, where
high-titer serum NAb correlate with more MRI lesions dur-
ing IFN therapy, presumably from lower circulating IFN-β lev-
els. However, effects on clinical activity are difficult to demon-
strate, likely due to complex pharmacokinetic effects of Abs to
IFN (55).
Would more frequent or higher doses of IFN-β reverse the IFN
signaling defect in those patients refractory to conventional doses
of IFN-β? In a very large study, patients with stable RRMS did not
have fewer relapses or MRI lesions from double doses of every-
other-day IFN-β-1b. Thus, the approved (single) dose of IFN-β is
optimal in early, stable RRMS. However, the higher dose was more
effective in preventing black hole development (12). The IFN sig-
naling defect is less common in stable RRMS than during active
and progressing MS (12). With thrice-weekly IFN-β-1a, there is
no difference in outcome between 22 and 44µg doses in RRMS
with low EDSS (early MS), but when the EDSS is >3.5 (later or
more severe MS), the 44-µg dose is superior in preventing relapses
and progression (56). This suggests complex interactions between
IFN-β dose and injection frequency, NAb, and form or severity
of MS.
Unexplored issues remain with effects of excessive or defec-
tive IFN signature and responses to therapy. Is the incidence of
infections and cancer reduced by IFN therapy? In a large, but
only 2-year, study, there were fewer bladder infections and cancers
in the intramuscular IFN-β-1a subgroup compared to placebo
and fingolimod (57). Does correction of low IFN levels restore
immunity and promote neuroprotection? Is the aging process
slowed with normal or high levels of IFN-β, a protein that is
cell-protective?
IFN REGULATION IN SLE, SJÖGREN’S SYNDROME, AND NMO
IS OPPOSITE OF REGULATION IN MS
Neuromyelitis optica is a demyelinating disease that until recently
was simply considered a severe variant of MS. We have argued that
NMO is actually much closer to SLE and Sjögren’s syndrome, and
that it differs fundamentally from MS (Table 2) (47, 58).
CNS Sjögren’s syndrome affects younger women, 18–40 years-
old, predominantly non-white, whereas the primary form affects
45–55-year-old women. The clinical appearance is similar to NMO
(Devic’s disease), with devastating spinal cord or optic nerve
lesions. Onset of devastating CNS symptoms is over hours to days,
may follow infections, and recovery is often incomplete. Spinal
cord lesions in CNS Sjögren’s syndrome and NMO span 3 or more
vertebral segments, are central or holocord, are demyelinating but
also necrotic, are sometimes so severe that there is spinal cord
swelling. Optic nerve lesions are also highly destructive, and can
have bilateral onset. In contrast, MS lesions are smaller, are <1
cord segment long, are often acentric or subpial, are not necrotic,
and typically recover partially or completely, and optic neuritis is
unilateral.
The type I IFN signature is supra-normal in NMO, but dimin-
ished in MS (38). NMO patients who were partially treated with
low-dose steroids or plaquenil have normal levels of serum type
I IFN activity (6× greater than in MS), and in vitro induction of
P-Y-STAT-1, MxA, and viperin is excessive compared to healthy
controls (Figure 3). In contrast, therapy-naïve MS patients have
low levels of type I IFN activity and subnormal responses to IFN-β
in vitro.
Neuromyelitis optica is now defined by MRI criteria – longitu-
dinally extensive cord MRI lesions, and by serology – NMO-IgG
positive. However, some cord lesions are too short on MRI and
less devastating than expected, and only 60–70% of suspected
NMO patients are NMO-IgG positive. Moreover, there is signifi-
cant clinical overlap with CNS Sjögren’s disease, but here only 50%
are NMO-IgG positive. Using serum type I IFN activity as a dis-
criminator, ROC analysis shows a 35-fold ability to discriminate
between NMO/CNS Sjögren’s and MS. This and other tests that
could help discriminate between NMO and MS would aid in ther-
apeutic decisions. This is important because disease mechanisms
and responses to therapy differ between the two. For instance,
IFN-β does not benefit or worsens NMO, but IFN-β is therapeutic
in MS.
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FIGURE 3 | (A) Serum IFN-α/β activity is low in MS vs. NL, and high in SLE.
IFN-α/β activity was obtained from real-time PCR of three expressed genes in
WISH epithelial cells. N =272 SLE on minimal Rx, 150 healthy controls, 57
stable RRMS naïve to Rx. Red bars= log median± interquartile range
(Kruskal–Wallis test). Medians=3.1 for SLE, 0.4 for NL, and 0.1 for MS.
Ninety percent of MS levels are <0.5 U/ml. In NMO, IFN-α/β is in the normal
or SLE range. IFN-α/β detection is 0.1–0.5 U/ml, i.e., 20× more sensitive than
many available assays (38). (B) P-S-STAT1 levels in MNC from SLE, stable
NMO on minimal therapy, normal controls, stable RRMS, and active RRMS.
Unpaired t -test with equal variance.
IFN-β THERAPY OF MS: COGNITIVE BENEFITS, PROLONGED
SURVIVAL, INDUCTION OF ANTIOXIDANTS AND POSSIBLE
NEUROPROTECTION
One third of patients with pediatric-onset MS and clinically
isolated demyelinating syndromes (CISs) are abnormal on neu-
ropsychological testing. Untreated MS patients have significant
cognitive loss over time, to the point of falling several z-scores
below expected levels over 20 years (59). IFN-β improves cogni-
tion and slows cognitive loss in MS. The benefit was significant
in the 2-year pivotal trials and later studies for all three forms of
IFN-β-1. In the original IFN-β-1b trial, 32 patients tested over
2 years showed a dose-dependent improvement in visual-spatial
performance compared to placebo (19). Benefit correlated with
diminished MRI activity. The periventricular predilection of MS
lesions could selectively disrupt the input and output of the cal-
carine cortex. We hypothesized that IFN-β quelled inflammation
in these sites to enhance visuospatial performance (60).
Sixteen of these patients were studied in a long-term follow-
up, 16 years after starting IFN-β (61). They did not remain in the
original placebo, 50µg, and 250µg qod subgroups for more than
3 years, because at study end in 1993, all of these patients remained
on IFN-β or started IFN-β de novo when the drug was approved.
Fifteen of 16 patients were taking IFN-β at the 16-year point. The
natural history of progressive decline of cognition in MS would
lead one to expect loss of cognitive function after this long period,
but there was no or only minimal cognitive decline at 16 years.
This indicates that IFN-β-1b had a pronounced long-term benefit
on cognition in active RRMS.
Interferon-β-1b therapy prevents death. In the pivotal IFN-β-
1b study, there was a 5-year randomized disparity in placebo vs.
IFN-β treatment, and then all patients started standard-of-care
treatments. Five years of IFN-β therapy increased later survival by
7 years over a 21-year observation, a 47% reduction in mortality
(62). What is the mechanism of the profound effect of IFN-β on
survival in MS? Baseline pre-therapy male sex, high T2 MRI bur-
den of disease, and high EDSS all were increased in those who
died, but IFN-β-1b had an independent effect (nearly 50% reduc-
tion in mortality) for each variable. On-study responses such as
new relapses, T2 lesions, or neutralizing Ab titers, did not signif-
icantly change mortality. This suggests that IFN-β has effects on
MS that are beyond the usual trial readouts of relapses and MRI
lesions.
Over the first 16 years of this study, those who were on IFN-β-1b
therapy for>80% of the time (restricted to a subset of the original
250µg IFN-β group), compared to those treated only <10% of
the time (a subset of the original placebo) were∼60% less likely to
require a cane or wheelchair or to develop SPMS (63). The delay
of onset of SPMS in the low medication usage group was 12 year,
vs. 18 year in the high medication usage group. Note that these
data are based on correlations, and other factors could influence
medication use.
Interferon-β’s benefit on mortality in MS cannot be explained
by a simple Th1–Th2 shift. Could IFN-β induce genes that would
protect or repair brain cells? The likelihood that type I IFNs evolved
to have cytoprotective and neuroprotective effects was introduced
in the Prolog. Can we measure gene induction after IFN-β therapy?
Multiple sclerosis patients with carefully defined clinical dis-
ease activity who had been on prolonged IFN-β-1b therapy were
studied more than 60 h after their last injections, and then exactly
4, 18, and 42 h after an injection of IFN-β. RNA from MNC was
run on Affymetrix Hu133A and also all-exon arrays. IFN caused a
rapid (4 h) and intermediate (18 h) induction of ISGs at 4 and 18 h,
and levels then fell back to baseline at 42 h (33). Surprisingly, after
the 60-h washout, there remained an RNA signature for upregula-
tion of scores of genes that control fatty acid oxidation, apoptosis,
energy metabolism, and cytoprotection, such as Nrf2 (64). These
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patients had been on IFN-β-1b therapy for 2–18 years. It is likely
that long-term IFN-β therapy alters the set-point for control of
cell metabolism and neuroprotection in blood and CNS cells. Glu-
cocorticosteroids, stress, smoking, and obesity increase oxidative
stress. Some of these environmental factors increase MS sever-
ity. Perhaps induction of cytoprotective genes explains some of
the benefits of IFN-β-1b therapy on MRI black hole formation,
cognition, and survival.
Multiple sclerosis brain lesions are an ominous predictor of
shorter survival (62). MRI lesions predict mortality in untreated
and treated MS patents. IFN-β therapy reduces new MRI T2 and
new Gd+ lesions by 85% (48, 65) and reduces formation of perma-
nent T1 MRI lesions (“black holes”) (12). Black holes are a marker
for inflammatory damage as well as lack of repair. IFN-β ther-
apy prevents inflammation and may enhance repair. IFN-β also
increases NAA concentration in brain neurons on MRS imaging
(66), presumably by rescuing unhealthy neurons from death. IFN-
β-1b therapy in MS has delayed benefits on cognition (19). Though
speculative, fewer MRI lesions during therapy may increase sur-
vival. CNS lesions could disrupt trophic outputs to the rest of
the body or disrupt immune regulation. For instance, sympa-
thetic nerves bathe the spleen and secondary lymphoid organs
with inhibitory catecholamines and neuropeptides. Spinal cord
lesions that disrupt these SNS pathways will disinhibit the immune
system, provoke and amplify autoimmune disease, and correlate
with presence of progressive forms of MS (67, 68). Thus, new MRI
lesions, permanent T1 black holes, cold purple feet from SNS dam-
age in SPMS, cognitive loss, and even death may be interrelated
phenomena and appear to be thwarted by IFN-β therapy.
COMBINATION THERAPY WITH OTHER AGENTS CAN
PERTURB THE IFN SIGNALING PATHWAY
Intrinsic or disease-specific responses to IFN can modify the
course of an autoimmune disease, but can be altered by exogenous
triggers or by IFN-β therapy. Viruses for instance, cause exacer-
bations of MS, likely by activating not just IFNs, but many other
facets of immunity. Could other agents modify intrinsic IFN lev-
els or the effects of therapy? Two examples include statins and
vitamin D.
Statins lower cholesterol, but are also anti-inflammatory. It
would seem reasonable to combine statins with IFN-β to treat the
inflammation of MS. Statins appeared to reduce MRI lesions (69).
However, only active patients entered this uncontrolled study, and
the 41% reduction in MRI activity is what would be expected due
to regression to the mean without any therapy (70). Several small
studies seemed to show benefit of combining statins and IFN-β.
However, a controlled trial of RRMS patients on subcutaneous
IFN-β-1a therapy who were then randomized to IFN-β alone or
IFN-β plus high-dose atorvastatin (40–80 mg/day) showed that
the combination provoked MRI and clinical exacerbations (33).
A larger study of IFN-β-1a± atorvastatin showed similar trends,
especially in a composite score of MRI and clinical MS activ-
ity (71). The presumed synergy between two anti-inflammatory
agents did not materialize because statins actually block IFN sig-
naling. In vitro, statins cause a dose- and time-dependent block
of IFN-β-induced phosphorylation of STAT1 (38) (Figure 4).
In vivo, patients on various IFN-β therapies plus various forms
of statin were tested after washing out both drugs and then per-
forming IFN-β induction kinetics after: (1) adding IFN-β alone,
and later repeating with (2) IFN-β plus high-dose statins. A dose
of statins blocked IFN-β formation of P-Y-STAT, but not P-S-
STAT1, and inhibited production of downstream proteins such
as MxA and viperin. This cautionary tale suggests that statins
could block the benefit of IFN-β, and that if both are needed,
then the posology of therapy should be adjusted so statins are
given at a time when they will have the least effect on the IFN
injection.
Vitamin D has pleiotropic effects on immunity. It enhances
macrophage function, but also induces IL-10. Serum vitamin D
levels vary, due to lifestyle, skin color, and seasonal sunlight. Low
levels are linked to onset of MS, and exacerbations once MS
has developed. Could this inexpensive, sometimes free, agent be
added to IFN-β? Several small studies show no additive effects,
including one that was designated as class I evidence by the jour-
nal, Neurology (72). Unfortunately, a significant mismatch in
the baseline demographics favored IFN-β monotherapy and the
results are not at all conclusive. Another study showed no additive
effect with subcutaneous IFN-β-1a (73). In a larger controlled
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FIGURE 4 | (A) In vitro atorvastatin reduces IFN-β effects. MNC from 21
therapy-naïve RRMS were pretreated 24 h with 10µM atorvastatin, then
induced with 160 U/ml IFN-β-1b for 45 min (phosphorylated/activated P-STAT
transcription factors) and for 24 h (induced unphosphorylated STAT1, STAT2,
also MxA and IRF-1). Proteins quantified with Western blots, normalized with
actin. Percentage change= statin-treated vs. no-statin (100%). *p<0.05,
**p<0.001 vs. no-statin control. MEV=100µM mevalonate to reverse statin
effect. Mean±SEM; 21 replications (38). (B) In vivo statins reduce IFN-β
therapy induction of serum type I IFN activity. Sera were obtained at 8 a.m.
after statin washout or long-term statin alone, and then exactly 4 h after IFN-β
injections or high-dose statins plus 4 h IFN-β. Fourteen stable RRMS.
**p<0.001 vs. IFN alone (paired t -test). Mean±SEM (38).
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study, however, vitamin D3 added to IFN-β-1b reduced new
MRI lesions compared to IFN-β alone (74). IFN-β also appears
to increase serum vitamin D levels (75). Many other studies
of vitamin D plus IFN-β in MS, and vitamin D alone in SLE,
are in progress. It is hoped that current, partially effective and
expensive, therapies will be enhanced by a second inexpensive
agent.
SUMMARY
• Type I Interferons (IFN-α/β) control viruses, cancer, cell
proliferation, and immunity
• Type I IFNs were present in early fish, 400 million years ago
• Interferons evolved complex responses to viruses over eons; ver-
tebrate survival likely was enhanced by cytoprotective effects of
IFNs
• Interferons regulate∼1000 genes
• Plasmacytoid dendritic cells produce IFN-α and some IFN-β;
fibroblasts produce IFN-β
• The IFNAR activates the STAT1 transcription factor on tyrosine,
allowing DNA binding
• Some genes are further induced by a second phosphorylation
on serine (P-S-STAT1)
• Viruses bind TLR, RIG-I, and MDA5. These activate IRF3, then
IFN-β and IFN-α1, then IRF7, then many subtypes of IFN-α
• Viruses, exogenous, and perhaps endogenous, trigger IFN
production
• High serum and organ IFN levels are linked to SLE, Sjögren’s
syndrome, Aicardi–Goutières, and Cree encephalitis, as well as
CNS Sjögren’s and NMO
• Interferon-α treatment triggers and amplifies SLE
• Serum IFN levels are low in MS
• Responses to in vitro IFN-β are low in MNCs from untreated
MS patients during clinical activity and progression
• Responses to in vivo IFN-β therapy are low in MS during clin-
ical activity and progression, measured by gene induction and
activation of transcription factors
• Low responses to IFN during clinically active MS are linked to
low levels of P-S-STAT1
• Interferon-β is therapeutic in MS, and may be most effective in
patients with low IFN responses
• Some drugs such as statins, block type I IFN signaling, and
worsen MS
• The high IFN responses in NMO and CNS Sjögren’s disease can
be used to differentiate them from the low responses in MS
ACKNOWLEDGMENTS
Grant support from the National MS Society (RG#4509A) to
Anthony T. Reder and Xuan Feng.
REFERENCES
1. Fox BA, Sheppard PO, O’Hara
PJ. The role of genomic data
in the discovery, annotation and
evolutionary interpretation of the
interferon-lambda family. PLoS One
(2009) 4(3):e4933. doi:10.1371/
journal.pone.0004933
2. Robertsen B. The interferon system
of teleost fish. Fish Shellfish Immunol
(2006) 20(2):172–91.
3. Der SD, Zhou A, Williams BR, Sil-
verman RH. Identification of genes
differentially regulated by interferon
α, β, or γ using oligonucleotide
arrays. Proc Natl Acad Sci U S
A (1998) 95(26):15623–8. doi:10.
1073/pnas.95.26.15623
4. Reder AT, Velichko S, Yamaguchi
KD, Hamamcioglu K, Ku K, Beek-
man J, et al. Interferon-β-1b induces
transient and variable gene expres-
sion in relapsing-remitting mul-
tiple sclerosis patients, indepen-
dent of neutralizing antibodies or
changes in IFN receptor RNA
expression. J Interferon Cytokine Res
(2008) 28:317–31. doi:10.1089/jir.
2007.0131
5. Sadzak I, Schiff M, Gattermeier I,
Glinitzer R, Sauer I, Saalmuller A,
et al. Recruitment of Stat1 to chro-
matin is required for interferon-
induced serine phosphorylation of
Stat1 transactivation domain. Proc
Natl Acad Sci U S A (2008)
105(26):8944–9. doi:10.1073/pnas.
0801794105
6. Platanias LC. Mechanisms of type-
I- and type-II-interferon-mediated
signalling. Nat Rev Immunol (2005)
5(5):375–86. doi:10.1038/nri1604
7. Feng X, Yau D, Holbrook C,
Reder AT. Type I interferons inhibit
interleukin-10 production in acti-
vated human monocytes and stim-
ulate IL-10 in T cells: implications
for Th1-mediated diseases. J Inter-
feron Cytokine Res (2002) 22:311–9.
doi:10.1089/107999002753675730
8. Jaitin DA, Roisman LC, Jaks E,
Gavutis M, Piehler J, Van der Hey-
den J, et al. Inquiring into the
differential action of interferons
(IFNs): an IFN-α2 mutant with
enhanced affinity to IFNAR1 is
functionally similar to IFN-β. Mol
Cell Biol (2006) 26:1888–97. doi:10.
1128/MCB.26.5.1888-1897.2006
9. Vitale G, de Herder WW, van
Koetsveld PM, Waaijers M, Scho-
ordijk W, Croze E, et al. IFN-
β is a highly potent inhibitor
of gastroenteropancreatic neuroen-
docrine tumor cell growth in vitro.
Cancer Res (2006) 66:554–62. doi:
10.1158/0008-5472.CAN-05-3043
10. Smith RA, Norris F, Palmer D,
Bernhardt L, Wills RJ. Distribu-
tion of alpha interferon in serum
and cerebrospinal fluid after sys-
temic administration. Clin Pharma-
col Ther (1985) 37:85–8. doi:10.
1038/clpt.1985.16
11. Rudick RA, Ransohoff RM, Pep-
pler R, VanderBrug Medendorp S,
Lehmann P, Alam J. Interferon beta
induces interleukin-10 expression:
relevance to multiple sclerosis. Ann
Neurol (1996) 40:618–27. doi:10.
1002/ana.410400412
12. Filippi M, Rocca MA, Camesasca
F, Cook S, O’Connor P, Arnason
BG, et al. Interferon beta-1b and
glatiramer acetate effects on perma-
nent black hole evolution. Neurol-
ogy (2011) 76(14):1222–8. doi:10.
1212/WNL.0b013e3182143577
13. Goelz SE, Hahm B, Luo Y, Eng-
ber T, Gorelik L. Positive reg-
ulation of neuroprotective genes
in the CNS of mice with exper-
imental autoimmune encephalitis
(EAE) by interferon beta (IFN-
β) treatment. Neurology (2007)
68(Suppl 1):A118.
14. Matsumoto M, Funami K, Tan-
abe M, Oshiumi H, Shingai M,
Seto Y, et al. Subcellular localiza-
tion of toll-like receptor 3 in human
dendritic cells. J Immunol (2003)
171(6):3154–62.
15. Ning S, Pagano JS, Barber GN.
IRF7: activation, regulation, modi-
fication and function. Genes Immun
(2011) 12(6):399–414. doi:10.1038/
gene.2011.21
16. Traugott U, Lebon P. Multiple scle-
rosis: involvement of interferons
in lesion pathogenesis. Ann Neurol
(1988) 24:243–51. doi:10.1002/ana.
410240211
17. Juengling FD, Ebert D, Gut O, Engel-
brecht MA, Rasenack J, Nitzsche EU,
et al. Prefrontal cortical hypometab-
olism during low-dose interferon
alpha treatment. Psychopharmacol-
ogy (2000) 152:383–9. doi:10.1007/
s002130000549
18. Moschos M, Manesis E, Panagakis
E, Brouzas D, Hadziyannis S, Theo-
dossiadis G. The effect of low-
dose interferon treatment on visual
evoked potentials. Doc Ophthal-
mol (1998) 94:215–21. doi:10.1007/
BF02582980
19. Pliskin NH, Hamer DP, Goldstein
DS, Towle VL, Reder AT, Noronha
A, et al. The effects of interferon-
beta on cognitive function in mul-
tiple sclerosis patients receiving
interferon β−1β. Neurology (1996)
47:1463–8. doi:10.1212/WNL.47.6.
1463
20. Ball EA, Sambo MR, Martins
M, Trovoada MJ, Benchimol C,
Costa J, et al. IFNAR1 controls
progression to cerebral malaria in
children and CD8+ T cell brain
pathology in Plasmodium berghei-
infected mice. J Immunol (2013)
190(10):5118–27. doi:10.4049/
jimmunol.1300114
21. Stetson DB, Ko JS, Heidmann T,
Medzhitov R. Trex1 prevents cell-
intrinsic initiation of autoimmu-
nity. Cell (2008) 134(4):587–98. doi:
10.1016/j.cell.2008.06.032
22. Goutières F. Aicardi-
Goutières syndrome. Brain
Dev (2005) 27(3):201–6.
doi:10.1016/j.braindev.2003.12.011
www.frontiersin.org September 2013 | Volume 4 | Article 281 | 11
Reder and Feng Interferon in autoimmunity and MS
23. Black DN, Watters GV, Andermann
E, Dumont C, Kabay ME, Kaplan P,
et al. Encephalitis among Cree chil-
dren in Northern Quebec. Ann Neu-
rol (1988) 24:483–9. doi:10.1002/
ana.410240402
24. Kavanagh D, Spitzer D, Kothari PH,
Shaikh A, Liszewski MK, Richards
A, et al. New roles for the major
human 3’-5’ exonuclease TREX1 in
human disease. Cell Cycle (2008)
7(12):1718–25. doi:10.4161/cc.7.12.
6162
25. Campbell IL, Krucker T, Steffensen
S, Akwa Y, Powell HC, Lane T, et
al. Structural and functional neu-
ropathology in transgenic mice with
CNS expression of IFN-α. Brain Res
(1999) 835(1):46–61. doi:10.1016/
S0006-8993(99)01328-1
26. Cuadrado E, Jansen MH, Anink
J, De Filippis L, Vescovi AL,
Watts C, et al. Chronic exposure
of astrocytes to interferon-alpha
reveals molecular changes related to
Aicardi-Goutieres syndrome. Brain
(2013) 136(Pt 1):245–58. doi:10.
1093/brain/aws321
27. Perron H, Germi R, Bernard C,
Garcia-Montojo M, Deluen C,
Farinelli L, et al. Human endoge-
nous retrovirus type W envelope
expression in blood and brain
cells provides new insights into
multiple sclerosis disease. Mult
Scler (2012) 18(12):1721–36. doi:
10.1177/1352458512441381
28. Reder AT. Regulation of production
of adrenocorticotropin-like pro-
teins in human mononuclear cells.
Immunology (1992) 77:436–42.
29. Muller H, Hammes E, Hiemke C,
Hess G. Interferon-alpha-2-induced
stimulation of ACTH and cortisol
secretion in man. Neuroendocrinol-
ogy (1991) 54(5):499–503. doi:10.
1159/000125944
30. Reder AT, Lowy MT. Interferon-β
treatment does not elevate cortisol
in multiple sclerosis. J Interferon Res
(1992) 12(3):195–8. doi:10.1089/jir.
1992.12.195
31. Qu ZX, Pliskin N, Jensen MW,
White D, Arnason BGW. Etretinate
augments interferon beta-1b effects
on suppressor cells in multiple scle-
rosis. Arch Neurol (2001) 58:87–90.
doi:10.1001/archneur.58.1.87
32. Feng X, Petraglia AL, Chen M,
Byskosh PV, Boos MD, Reder
AT. Low expression of interferon-
stimulated genes in active multi-
ple sclerosis is linked to subnormal
phosphorylation of STAT1. J Neu-
roimmunol (2002) 129:105–15. doi:
10.1016/S0165-5728(02)00182-0
33. Birnbaum G, Cree B, Altafullah
I, Zinser M, Reder A. Combining
beta interferon and atorvastatin
increases disease activity in mul-
tiple sclerosis. Neurology (2008)
71:1390–5. doi:10.1212/01.wnl.
0000319698.40024.1c
34. Read AF, Graham AL, Raberg L.
Animal defenses against infectious
agents: is damage control more
important than pathogen control.
PLoS Biol (2008) 6(12):e4. doi:10.
1371/journal.pbio.1000004
35. Day T, Graham AL, Read AF. Evo-
lution of parasite virulence when
host responses cause disease. Proc
Biol Sci (2007) 274(1626):2685–92.
doi:10.1098/rspb.2007.0809
36. Capobianchi MR, Mattana P, Gen-
tile M, Conciatori GC, Ankel H,
Dianzani F. Role of glycosilation
in the susceptibility of “acid labile”
interferon alpha to acid treatment.
J Biol Regul Homeost Agents (1991)
5(4):147–53.
37. Niewold TB, Hua J, Lehman TJ,
Harley JB, Crow MK. High serum
IFN-alpha activity is a heritable
risk factor for systemic lupus ery-
thematosus. Genes Immun (2007)
8(6):492–502. doi:10.1038/sj.gene.
6364408
38. Feng X, Han D, Kilaru BK, Franek
BS, Niewold TB, Reder AT. Inhi-
bition of interferon-beta responses
in multiple sclerosis immune cells
associated with high-dose statins.
Arch Neurol (2012) 69(10):1303–9.
doi:10.1001/archneurol.2012.465
39. Diamond B, Kowal C, Huerta PT,
Aranow C, Mackay M, DeGior-
gio LA, et al. Immunity and
acquired alterations in cognition
and emotion: lessons from SLE. Adv
Immunol (2006) 89:289–320. doi:
10.1016/S0065-2776(05)89007-8
40. Reder AT. Multiple sclerosis.
In: Gilman S, editor. Neu-
robase, Medlink Neurology.
San Diego: Medlink Corpora-
tion@www.medlink.com (2012). p.
1–147.
41. Farez MF, Correale J. Yellow
fever vaccination and increased
relapse rate in travelers with
multiple sclerosis. Arch Neu-
rol (2011) 68(10):1267–71.
doi:10.1001/archneurol.2011.131
42. Panitch HS, Bever CT Jr, Katz E,
Johnson KP. Upper respiratory tract
infections trigger attacks of multi-
ple sclerosis in patients treated with
interferon. J Neuroimmunol (1991)
35(Suppl 1):125. doi:10.1016/0165-
5728(91)91073-L
43. Comabella M, Lunemann JD, Rio
J, Sanchez A, Lopez C, Julia E, et
al. A type I interferon signature
in monocytes is associated with
poor response to interferon-beta
in multiple sclerosis. Brain (2009)
132(Pt 12):3353–65. doi:10.1093/
brain/awp228
44. Rudick RA, Rani MR, Xu Y, Lee
JC, Na J, Shrock J, et al. Excessive
biologic response to IFNbeta is
associated with poor treatment
response in patients with mul-
tiple sclerosis. PLoS One (2011)
6(5):e19262. doi:10.1371/journal.
pone.0019262
45. Patsopoulos NA, Esposito F, Reis-
chl J, Lehr S, Bauer D, Heubach J,
et al. Genome-wide meta-analysis
identifies novel multiple sclero-
sis susceptibility loci. Ann Neurol
(2011) 70(6):897–912. doi:10.1002/
ana.22609
46. Byskosh PV, Reder AT. Interferon-
β effects on cytokine mRNA in
peripheral mononuclear cells in
multiple sclerosis. Mult Scler (1996)
1:262–9.
47. Javed A, Reder AT. Therapeu-
tic role of beta-interferons in
multiple sclerosis. Pharmacol Ther
(2006) 110:35–56. doi:10.1016/j.
pharmthera.2005.08.011
48. The IFN-Beta Multiple Sclerosis
Study Group. Interferon beta-1b
is effective in relapsing-remitting
multiple sclerosis. I. Clinical results
of a multicenter, randomized,
double-blind, placebo-controlled
trial. Neurology (1993) 43:655–61.
doi:10.1212/WNL.43.4.655
49. Byskosh PV, Reder AT. Interferon-
β-1b effects on cytokine mRNA
in multiple sclerosis. Ann Neurol
(1995) 38:340A.
50. Decker T, Kovarik P. Serine phos-
phorylation of STATs. Oncogene
(2000) 19:2628–37. doi:10.1038/sj.
onc.1203481
51. Noronha A, Toscas A, Jensen MA.
Interferon beta augments suppres-
sor cell function in multiple sclero-
sis. Ann Neurol (1990) 27:207–10.
doi:10.1002/ana.410270219
52. Miravalle A, Jensen R, Kinkel RP.
Immune reconstitution inflamma-
tory syndrome in patients with mul-
tiple sclerosis following cessation of
natalizumab therapy. Arch Neurol
(2011) 68(2):186–91. doi:10.1001/
archneurol.2010.257
53. Genc K, Dona DL, Reder AT.
Increased CD80+ B cells in active
multiple sclerosis, and reversal by
IFNβ-1b therapy. J Clin Invest
(1997) 99:2664–71. doi:10.1172/
JCI119455
54. Reder AT, Li L, Feng X. Disease activ-
ity affects responses to IFN-β-1b
therapy in multiple sclerosis. Neu-
rology (2011) 76(Suppl 3):01.215.
55. Reder AT. Neutralizing antibodies in
multiple sclerosis: a complex impact
on interferon responses, magnetic
resonance imaging findings, and
clinical outcomes. Mul Scler (2007)
13(Suppl):553–62.
56. Ebers GC. Randomised double-
blind placebo-controlled study
of interferon β-1a in relaps-
ing/remitting multiple sclerosis.
PRISMS (Prevention of Relapses
and Disability by Interferon β-1a
Subcutaneously in Multiple Scle-
rosis) Study Group. Lancet (1998)
352:1498–504.
57. Cohen JA, Barkhof F, Comi G, Har-
tung HP, Khatri BO, Montalban
X, et al. Oral fingolimod or intra-
muscular interferon for relapsing
multiple sclerosis. N Engl J Med
(2010) 362(5):402–15. doi:10.1056/
NEJMoa0907839
58. Javed A, Balabanov R, Arnason
BGW, Kelly TJ, Sweiss NJ, Pytel P,
et al. Minor salivary gland inflam-
mation in Devic’s disease and lon-
gitudinally extensive myelitis. Mult
Scler (2008) 14:809–14. doi:10.
1177/1352458508088941
59. Langdon D, Reder A, Ebers GC,
Goodin D, Traboulsee A, Beckmann
K, et al. Cognition in the later
stages of multiple sclerosis: cog-
nitive results from the betaferon
16-year long-term follow-up study
(2007) ECTRIMS, Multiple Sclerosis
13(Suppl 2):P749, S226, 2007.
60. Pliskin NH, Reder AT, Gold-
stein DS. Neuropsychological
effects of interferon therapy. In:
Reder AT, editor. Interferon Ther-
apy of Multiple Sclerosis. New
York: Marcel Dekker, Inc (1997).
p. 139–60.
61. Lacy M, Hauser M, Pliskin N,
Assuras S, Valentine MO, Reder A.
The effects of long-term interferon-
beta-1b treatment on cognitive
functioning in multiple sclerosis:
a 16-year longitudinal study. Mult
Scler (2013).
62. Goodin DS, Reder AT, Ebers GC,
Cutter G, Kremenchutzky M, Oger
J, et al. Survival in MS: a ran-
domized cohort study 21 years
after the start of the pivotal
IFNbeta-1b trial. Neurology (2012)
78(17):1315–22. doi:10.1212/WNL.
0b013e3182535cf6
63. Ebers GC, Traboulsee A, Li D, Lang-
don D, Reder AT, Goodin DS, et
al. Analysis of clinical outcomes
according to original treatment
groups 16 years after the pivotal
IFNB-1b trial. J Neurol Neurosurg
Psychiatry (2010) 81(8):907–12.
doi:10.1136/jnnp.2009.204123
64. Croze E, Yamaguchi KD, Knap-
pertz V, Reder AT, Salamon H.
Interferon-beta-1b-induced short-
Frontiers in Immunology | Molecular Innate Immunity September 2013 | Volume 4 | Article 281 | 12
Reder and Feng Interferon in autoimmunity and MS
and long-term signatures of treat-
ment activity in multiple sclerosis.
Pharmacogenomics J (2012) 19:1–9.
doi:10.1038/tpj.2012.27
65. The IFN-Beta Multiple Sclerosis
Study Group. Interferon beta-1b
is effective in relapsing-remitting
multiple sclerosis. II. MRI analy-
sis results of a multicenter, ran-
domized, double-blind, placebo-
controlled trial. Neurology (1993)
43:662–7. doi:10.1212/WNL.43.4.
662
66. Narayanan S, De Stefano N, Francis
GS, Arnaoutelis R, Caramanos
Z, Collins DL, et al. Axonal
metabolic recovery in multiple
sclerosis patients treated with
interferon β-1b. J Neurol (2001)
248:979–86. doi:10.1007/
s004150170052
67. Karaszewski JW, Reder AT, Maselli
R, Brown M,Arnason BGW. Sympa-
thetic skin responses are decreased
and lymphocyte beta-adrenergic
receptors are increased in progres-
sive multiple sclerosis. Ann Neurol
(1990) 27:366–72. doi:10.1002/ana.
410270404
68. Karaszewski JW, Reder AT, Anlar B,
Kim WC, Arnason BGW. Increased
lymphocyte beta-adrenergic recep-
tor density in progressive multiple
sclerosis is specific for the CD8+,
CD28- suppressor cell. Ann Neu-
rol (1991) 30:42–7. doi:10.1002/
ana.410300109
69. Vollmer T, Key L, Durkalski V,
Tyor W, Corboy J, Markovic-
Plese S, et al. Oral simvastatin
treatment in relapsing-remitting
multiple sclerosis. Lancet (2004)
363(9421):1607–8. doi:10.1016/
S0140-6736(04)16205-3
70. Zhao Y, Traboulsee A, Petkau
AJ, Li D. Regression of new
gadolinium enhancing lesion activ-
ity in relapsing-remitting multiple
sclerosis. Neurology (2008) 70(13
Pt 2):1092–7. doi:10.1212/01.wnl.
0000285426.73143.f7
71. Sorensen PS, Lycke J, Eralinna
JP, Edland A, Wu X, Frederik-
sen JL, et al. Simvastatin as add-
on therapy to interferon beta-
1a for relapsing-remitting multi-
ple sclerosis (SIMCOMBIN study):
a placebo-controlled randomised
phase 4 trial. Lancet Neurol (2011)
10(8):691–701. doi:10.1016/S1474-
4422(11)70144-2
72. Stein MS, Liu Y, Gray OM, Baker
JE, Kolbe SC, Ditchfield MR, et al.
A randomized trial of high-dose
vitamin D2 in relapsing-remitting
multiple sclerosis. Neurology (2011)
77(17):1611–8. doi:10.1212/WNL.
0b013e3182343274
73. Loken-Amsrud KI, Holmoy T,
Bakke SJ, Beiske AG, Bjerve KS,
Bjornara BT, et al. Vitamin D
and disease activity in multi-
ple sclerosis before and during
interferon-beta treatment. Neurol-
ogy (2012) 79(3):267–73. doi:10.
1212/WNL.0b013e31825fdf01
74. Soilu-Hanninen M, Aivo J, Lind-
strom BM, Elovaara I, Sumelahti
ML, Farkkila M, et al. A randomised,
double blind, placebo controlled
trial with vitamin D3 as an add
on treatment to interferon beta-
1b in patients with multiple scle-
rosis. J Neurol Neurosurg Psychiatry
(2012) 83(5):565–71. doi:10.1136/
jnnp-2011-301876
75. Stewart N, Simpson S Jr, van der
Mei I, Ponsonby AL, Blizzard L,
Dwyer T, et al. Interferon-beta
and serum 25-hydroxyvitamin
D interact to modulate relapse
risk in MS. Neurology (2012)
79(3):254–60. doi:10.1212/WNL.
0b013e31825fded9
76. O’Shea JJ, Visconti R. Type 1 IFNs
and regulation of TH1 responses:
enigmas both resolved and emerge.
Nat Immunol (2000) 1(1):17–9. doi:
10.1038/76872
77. Wingerchuk DM, Lennon VA,
Pittock SJ, Lucchinetti CF, Wein-
shenker BG. Revised diagnostic
criteria for neuromyelitis optica.
Neurology (2006) 66(10):1485–9.
doi:10.1212/01.wnl.0000216139.
44259.74
78. Pittock SJ, Weinshenker BG,
Lucchinetti CF, Wingerchuk
DM, Corboy JR, Lennon VA.
Neuromyelitis optica brain
lesions localized at sites of
high aquaporin 4 expression.
Arch Neurol (2006) 63(7):964–8.
doi:10.1001/archneur.63.7.964
79. Ren Z, Wang Y, Duan T, Patel J,
Liggett T, Loda E, et al. Cross-
immunoreactivity between bac-
terial aquaporin-Z and human
aquaporin-4: potential rele-
vance to neuromyelitis optica. J
Immunol (2012) 189(9):4602–11.
doi:10.4049/jimmunol.1200486
Conflict of Interest Statement: Bayer
Schering Pharma, Biogen, Ezose, Gen-
zyme, Genentech, MedImmune, Novar-
tis, Questcor, Sanofi-Aventis, Serono,
Teva – Travel expenses and time are cov-
ered to attend advisory boards and sci-
entific meetings; Grant support; Clini-
cal trials; and Data safety and monitor-
ing boards for clinical trials and devel-
opment of therapies for MS. NMSS –
Travel expenses for grant reviews.
Received: 09 July 2013; paper pending
published: 31 July 2013; accepted: 30
August 2013; published online: 17 Sep-
tember 2013.
Citation: Reder AT and Feng X (2013)
Aberrant type I interferon regulation
in autoimmunity: opposite directions in
MS and SLE, shaped by evolution and
body ecology. Front. Immunol. 4:281. doi:
10.3389/fimmu.2013.00281
This article was submitted to Molecular
Innate Immunity, a section of the journal
Frontiers in Immunology.
Copyright © 2013 Reder and Feng .
This is an open-access article distributed
under the terms of the Creative Com-
mons Attribution License (CC BY). The
use, distribution or reproduction in other
forums is permitted, provided the origi-
nal author(s) or licensor are credited and
that the original publication in this jour-
nal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.
www.frontiersin.org September 2013 | Volume 4 | Article 281 | 13
